Profile

QurCan Therapeutics is developing tissue and cell-targeted genetic medicine using its proprietary hybrid polymer-lipid nanoparticle, TERP technology. QurCan’s innovative TERP technology introduces a customizable surface chemistry for non-immunogenic repeated dosing and CNS delivery of RNA and DNA. The company is utilizing TERP technology to develop the next wave of nucleotide therapeutics for the treatment of rare neurodegenerative diseases.

QurCan Therapeutics Inc. logo

Website

qurcan.com

Contact


Event details

Date: January 13 - 15, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

21 in total